<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic disseminated candidiasis (hepatosplenic candidiasis)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic disseminated candidiasis (hepatosplenic candidiasis)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic disseminated candidiasis (hepatosplenic candidiasis)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John W Baddley, MD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan B Kruskal, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic disseminated candidiasis, also referred to as hepatosplenic candidiasis, is a form of infection due to <em>Candida</em> spp involving the liver and spleen; it typically occurs in patients with hematologic malignancy, following prolonged neutropenia [<a href="#rid1">1-3</a>]. </p><p>Clinical issues related to chronic disseminated candidiasis will be reviewed here. An overview of <em>Candida</em> infections as well as the clinical manifestations, diagnosis, and treatment of candidemia are presented separately. (See  <a class="medical medical_review" href="/d/html/2416.html" rel="external">"Overview of Candida infections"</a> and  <a class="medical medical_review" href="/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults"</a> and  <a class="medical medical_review" href="/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Chronic disseminated candidiasis usually occurs in patients with hematologic malignancy who have recently recovered from an episode of neutropenia [<a href="#rid4">4,5</a>]. Rare cases have been reported in patients with lymphoma, aplastic anemia, and sarcoma [<a href="#rid4">4-6</a>]. A small number of cases have been described among non-neutropenic patients [<a href="#rid7">7</a>].</p><p>Given that use of antifungal agents for prophylaxis and empiric treatment has become widespread, chronic disseminated candidiasis is relatively rare [<a href="#rid5">5,8</a>]. In one autopsy study including 329 hematopoietic cell transplant recipients, the rates of <em>Candida</em> infections and hepatosplenic candidiasis were lower among patients who received <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis than those who did not (8 versus 27 percent and 3 versus 16 percent, respectively) [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H4"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Risk factors for chronic disseminated candidiasis include [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute leukemia</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged neutropenia (&lt;500 neutrophils/microL for ≥10 days), particularly in the absence of antifungal prophylaxis</p><p class="bulletIndent1"><span class="glyph">●</span>Administration of broad-spectrum antibiotics</p><p class="bulletIndent1"><span class="glyph">●</span>Mucosal barrier disruption</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of an indwelling intravascular catheter</p><p class="bulletIndent1"><span class="glyph">●</span>Administration of total <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a></p><p></p><p class="headingAnchor" id="H1126895285"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of chronic disseminated candidiasis is not well understood. </p><p>In the context of prolonged neutropenia and a breach in mucosal integrity, the condition is thought to develop as a result of invasion of <em>Candida</em> species from the gastrointestinal tract into the bloodstream. However, candidemia during the period of neutropenia is not often documented. (See <a class="local">'Laboratory findings'</a> below.)</p><p>The portal system may receive the largest inoculum, leading to significant liver involvement [<a href="#rid5">5,9</a>]. Less often, involvement of the lungs, kidneys, and other organs also occurs [<a href="#rid2">2</a>]. </p><p>Factors supporting the role of the host immune response in pathogenesis include (1) histopathologic findings of granulomatous (rather than suppurative) inflammation and (2) development of symptoms and radiographic findings following neutrophil recovery (eg, as a form of immune reconstitution) [<a href="#rid2">2,10</a>].</p><p class="headingAnchor" id="H3247134660"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>Most cases of chronic disseminated candidiasis (in which an organism has been identified) have been attributable to <em>Candida albicans</em>. Other species, such as <em>Candida tropicalis</em>, <em>Candida parapsilosis</em>, <em>Candida glabrata</em>, and <em>Candida krusei</em>, have been reported occasionally [<a href="#rid4">4,7,11-13</a>]. (See  <a class="medical medical_review" href="/d/html/2442.html" rel="external">"Candidemia in adults: Epidemiology, microbiology, and pathogenesis"</a>.)</p><p>Blood cultures at the time of presentation are typically negative and antecedent candidemia (eg, at the time of neutropenia) is not often observed. (See <a class="local">'Laboratory findings'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H7"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>Patients with chronic disseminated candidiasis usually present within two weeks of neutrophil recovery; rarely, the presentation may be delayed up to a few months following neutrophil recovery. Very few cases present while neutropenic. In one series including 23 patients with acute leukemia and chronic disseminated candidiasis, clinical manifestations became apparent after neutrophil recovery in 85 percent of cases [<a href="#rid14">14</a>]. </p><p>The most common clinical feature of chronic disseminated candidiasis is fever that fails to respond to broad-spectrum antibacterial therapy. Additional symptoms may include right upper quadrant tenderness, hepatomegaly, splenomegaly, nausea, vomiting, and anorexia [<a href="#rid4">4,12,15,16</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Laboratory testing typically demonstrates an elevated serum alkaline phosphatase concentration [<a href="#rid5">5</a>]. In one study that included 28 patients with chronic disseminated candidiasis, three- to fivefold elevation of alkaline phosphatase was observed in 86 percent of cases [<a href="#rid15">15</a>]. However, this parameter should not be used to guide treatment response, as it usually lags behind clinical and radiographic improvement [<a href="#rid14">14</a>].</p><p>Less common laboratory abnormalities include mildly elevated aspartate aminotransferase, alanine aminotransferase, and bilirubin, as well as leukocytosis [<a href="#rid4">4,5</a>]. </p><p>The utility of serum beta-D-glucan measurement for diagnosis of chronic disseminated candidiasis is uncertain; no large studies have been performed to evaluate sensitivity and specificity. Several studies suggest potential utility of beta-D-glucan for predicting chronic disseminated candidiasis; however, these have used assay formats not available in the United States [<a href="#rid17">17,18</a>]. </p><p>Blood cultures at the time of presentation are typically negative and antecedent candidemia (eg, at the time of neutropenia) is not usually seen. In one series of 28 patients with chronic disseminated candidiasis, antecedent candidemia was documented in 32 percent of cases [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H10"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H2556491131"><span class="h2">Clinical approach</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whom to evaluate</strong> − Chronic disseminated candidiasis should be suspected in patients with recent neutropenia (usually within the preceding two weeks) who present with fever unresponsive to broad-spectrum antibiotic therapy; additional signs and symptoms may include right upper quadrant tenderness, hepatomegaly, splenomegaly, nausea, vomiting, and/or anorexia. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> − Patients with suspected chronic disseminated candidiasis should undergo diagnostic evaluation including laboratory testing (complete blood count, liver function tests, beta-D-glucan testing) and radiographic imaging (beginning with computed tomography [CT]). Blood cultures are also warranted; while often negative in patients with chronic disseminated candidiasis, they are important for evaluation of alternative diagnostic considerations. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Establishing a diagnosis </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Presumptive diagnosis</strong> − In most patients, a presumptive diagnosis of chronic disseminated candidiasis may be made based on clinical history, elevated liver function tests (particularly alkaline phosphatase concentration), and radiographic imaging demonstrating hypodense nodular lesions in the liver and/or spleen. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Definitive diagnosis via biopsy</strong> − A definitive diagnosis may be established by liver nodule biopsy in some cases; however, in practice, biopsy is done infrequently because the clinical picture and CT scan findings generally are adequate to make a diagnosis. In addition, biopsy is often not feasible since thrombocytopenia is common in patients at risk for chronic disseminated candidiasis.  </p><p></p><p class="bulletIndent2">Biopsy may demonstrate granulomas (<a class="graphic graphic_picture graphicRef81112" href="/d/graphic/81112.html" rel="external">picture 1</a>) [<a href="#rid4">4</a>]. Other findings may include necrosis with minimal inflammatory reaction (generally observed in the setting of neutropenia), or microabscesses with severe inflammatory reaction (typically observed after neutrophil recovery) [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent2">Yeasts and hyphal forms may be observed with silver methenamine staining [<a href="#rid2">2</a>]. Cultures of hepatic tissue obtained at biopsy are usually negative, particularly if antifungal therapy has been administered; hence, a negative tissue culture does not rule out the diagnosis.</p><p></p><p class="headingAnchor" id="H1881363656"><span class="h2">Radiographic imaging</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing </strong>− Imaging may be performed when investigating hepatosplenomegaly and abnormally elevated liver enzymes, or specifically to address suspected disseminated candidiasis. Radiographic imaging is more sensitive following neutrophil recovery than during neutropenia. In one series including five patients, serial CT scanning demonstrated disappearance of hepatic and/or splenic lesions during neutropenia with reappearance after neutrophil recovery [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of modality</strong> – Ultrasound is often the initial imaging modality and it may show normal appearing organs, diffusely enlarged organs, or organs containing multiple small low attenuation lesions widely scattered throughout the parenchyma. The sensitivity of ultrasonography is lower than CT or magnetic resonance imaging (MRI) [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1">CT is less costly than MRI; its sensitivity for detection of chronic disseminated candidiasis is 57 to 90 percent [<a href="#rid5">5,19,20</a>]. If CT does not demonstrate characteristic findings, MRI should be pursued, given higher sensitivity and specificity (100 and 96 percent, respectively) [<a href="#rid3">3</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging findings</strong> – Diffuse hepatic and splenic involvement may manifest as an entirely normal imaging appearance, enlarged liver and/or spleen, or multifocal small lesions diffusely distributed throughout the liver and/spleen. There is are no imaging findings specific to disseminated candidiasis; many diffuse infectious conditions may have overlapping imaging appearances. </p><p></p><p class="bulletIndent1">Imaging findings consist of multiple hypodense nodular lesions (representing microabscesses) in the liver and/or spleen; sometimes the kidneys are also involved (<a class="graphic graphic_diagnosticimage graphicRef64691" href="/d/graphic/64691.html" rel="external">image 1</a>) [<a href="#rid3">3,4,20</a>]. If the examination is performed with contrast, a central enhancement with a peripheral double ring (‘target lesion’) may be seen [<a href="#rid2">2</a>].</p><p></p><p class="headingAnchor" id="H1414584548"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculosis – Disseminated (miliary) tuberculosis can involve the liver and other organs. The diagnosis is suggested by the appearance on imaging and may be established by identifying the organism obtained from a biopsy sample in culture. (See  <a class="medical medical_review" href="/d/html/8024.html" rel="external">"Clinical manifestations, diagnosis, and treatment of miliary tuberculosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver abscess − Liver abscesses develop in the setting of biliary infection via direct spread or in the setting of diverticulitis or other cause of peritonitis (with spread of organisms to the liver via the portal circulation). They may also result from hematogenous seeding in the setting of systemic infection. Abscesses may be single or several may occur simultaneously. Their appearance varies depending on the duration; more mature abscesses are more likely to contain fluid components. The diagnosis is established by aspiration and culture of the abscess material. (See  <a class="medical medical_review" href="/d/html/2680.html" rel="external">"Pyogenic liver abscess"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relapsed hematologic malignancy – Fever in patients with history of hematologic malignancy should prompt consideration of disease relapse. The diagnosis is established by bone marrow biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoidosis – Sarcoidosis is a systemic granulomatous disease of unknown etiology characterized by the formation of non-necrotizing granulomas; hepatic involvement occurs in 5 to 20 percent of cases. Asymptomatic hepatic lesions may be first identified on the liver images of thoracic CT. On contrast-enhanced abdominal CT, the typical findings are hepatomegaly and numerous hypodense nodular lesions ranging in size from 1 mm to 3 cm. (See  <a class="medical medical_review" href="/d/html/4317.html" rel="external">"Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cirrhosis – Cirrhosis represents a late stage of hepatic fibrosis characterized by distortion of the hepatic architecture and the presence multiple regenerative nodules on radiographic imaging. (See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a>.) </p><p></p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H778293197"><span class="h2">Clinical approach</span><span class="headingEndMark"> — </span>Management of chronic disseminated candidiasis consists of antifungal therapy [<a href="#rid21">21</a>]. For patients with persistent fevers despite appropriate antifungal therapy (likely a reflection of immune reconstitution, given the typical clinical presentation following neutrophil recovery), adjuvant glucocorticoids may be administered. The duration of treatment should be tailored to individual circumstances. </p><p class="headingAnchor" id="H3671199572"><span class="h2">Antifungal therapy</span><span class="headingEndMark"> — </span>The optimal approach to treatment of chronic disseminated candidiasis is uncertain. We are in agreement with the 2016 Infectious Diseases Society of America guidelines for the management of candidiasis, which includes the following approach (<a class="graphic graphic_table graphicRef87678" href="/d/graphic/87678.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong> – Initial treatment consists of one of the following regimens for at least two weeks:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An echinocandin (dosing as follows, assuming normal hepatic function): </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Caspofungin – 70 mg loading dose, then 50 mg intravenously (IV) once daily</p><p class="bulletIndent3"><span class="glyph">-</span>Anidulafungin – 200 mg loading dose, then 100 mg IV once daily</p><p class="bulletIndent3"><span class="glyph">-</span>Micafungin – 100 mg IV once daily</p><p></p><p class="bulletIndent2"><strong>OR</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A lipid formulation of amphotericin B (3 to 5 mg/kg IV daily)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Step-down therapy</strong> – Once the patient has demonstrated improvement, step-down therapy with oral <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg [6 mg/kg] orally once daily) should be administered. Fever and other symptoms may be prolonged, even in the setting of effective antimicrobial therapy; in addition, radiographic findings may worsen over time due to persistent inflammation. (See <a class="local">'Follow-up management'</a> below.)</p><p></p><p class="bulletIndent1">For patients with infection due to a fluconazole-resistant isolate (such as patients who had antecedent candidemia wi<em>th C. glabrata</em> <em>or C. krusei</em>), we give step-down therapy with <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> or <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>. However, there is minimal experience with these agents for treatment of chronic disseminated candidiasis; they should be used only if the organism is known to be susceptible.</p><p></p><p class="bulletIndent1">The duration of treatment should be tailored to individual circumstances, as discussed below. (See <a class="local">'Follow-up management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting evidence</strong> – The above approach to antifungal therapy is supported by small open-label studies and case reports [<a href="#rid1">1,2,21</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">Amphotericin B deoxycholate</a> has been variably successful for treatment of chronic disseminated candidiasis [<a href="#rid14">14,22</a>]. In one retrospective study including 23 patients with acute leukemia and hepatosplenic candidiasis treated with amphotericin B (mean dose 4 g; median duration 112 days), the response rate was 82 percent [<a href="#rid14">14</a>]. Lipid formulations are less toxic and likely more effective than amphotericin B deoxycholate, perhaps due to better tissue concentrations [<a href="#rid5">5,23,24</a>], but some patients do not respond to either formulation [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">Echinocandins have been used successfully for treatment of chronic disseminated candidiasis in small case series and they are useful for treatment of infection due to fluconazole-resistant isolates [<a href="#rid25">25-29</a>]. However, treatment failures with echinocandins have been reported [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">Fluconazole</a> has been used successfully for treatment of hepatosplenic candidiasis in small case series [<a href="#rid12">12,16</a>]. In one retrospective study including 20 patients with chronic disseminated candidiasis treated with fluconazole (dose 100 to 400 mg; median duration 30 weeks), the response rate was 88 percent [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a> or <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> have been used successfully in small numbers of patients [<a href="#rid31">31,32</a>].</p><p></p><p class="headingAnchor" id="H1770422586"><span class="h2">Follow-up management</span><span class="headingEndMark"> — </span>Clinical<strong> </strong>manifestations generally improve within two to eight weeks after starting antifungal therapy. However, fever may persist for weeks despite appropriate antifungal treatment; this may reflect immune reconstitution, given the typical clinical presentation following neutrophil recovery [<a href="#rid33">33</a>]. In such cases, alternative causes of infection should be ruled out. (See <a class="local">'Pathogenesis'</a> above and  <a class="medical medical_review" href="/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent fever: role of adjuvant glucocorticoids </strong>– In patients with persistent fever despite appropriate antifungal therapy, we administer adjuvant glucocorticoid therapy (<a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 0.5 to 1 mg/kg orally daily) for a few weeks as a tapering dose, in conjunction with antifungal therapy [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1">This approach is supported by retrospective studies and case reports [<a href="#rid2">2,21,33,34</a>]. In one retrospective study including 10 patients with chronic disseminated candidiasis and persistent symptoms despite appropriate antifungal therapy who were treated with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (≥0.5 mg/kg per day for at least three weeks), fever and abdominal pain resolved shortly after starting prednisone (median four to five days) [<a href="#rid33">33</a>]. However, the time to radiographic resolution (mean 106 days) was similar to historical controls. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment duration guided by imaging </strong>– Follow-up computed tomography imaging should be obtained every two to three months [<a href="#rid1">1</a>]. Antifungal therapy should be continued until there is persistent resolution or calcification of the lesions on imaging, which usually takes approximately six months (<a class="graphic graphic_table graphicRef87678" href="/d/graphic/87678.html" rel="external">table 1</a>) [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1">Alkaline phosphatase should not be used alone to guide treatment response; it usually lags behind clinical and radiographic improvement [<a href="#rid14">14</a>].</p><p></p><p class="headingAnchor" id="H3999825066"><span class="h2">Subsequent immunosuppression</span><span class="headingEndMark"> — </span>Management of chronic disseminated candidiasis should not delay treatment of underlying malignancy; chronic disseminated candidiasis has been treated successfully through chemotherapy-induced neutropenia and hematopoietic cell transplantation without progression or breakthrough fungemia [<a href="#rid14">14,22,35</a>].</p><p>Following completion of treatment for chronic disseminated candidiasis, we continue <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (or restart if previously stopped) during subsequent periods of immunosuppression (such as chemotherapy or hematopoietic stem cell transplantation) to prevent relapse (<a class="graphic graphic_table graphicRef87678" href="/d/graphic/87678.html" rel="external">table 1</a>) [<a href="#rid1">1,12,16,22,29,32</a>]. This approach is supported by one series including 16 patients with chronic disseminated candidiasis treated with antifungal therapy and ongoing antineoplastic therapy; 12 patients had complete response to antifungal therapy, 2 had partial response, and 2 had progression of chronic disseminated candidiasis requiring further antifungal therapy [<a href="#rid22">22</a>]. </p><p class="headingAnchor" id="H1856686688"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104270.html" rel="external">"Society guideline links: Candidiasis"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> − Chronic disseminated candidiasis (also known as hepatosplenic candidiasis) is a form of infection due to <em>Candida</em> spp involving the liver and spleen; it typically occurs in patients with hematologic malignancy, following prolonged neutropenia. Given widespread use of antifungal agents in such patients, the condition has become relatively rare. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> − The pathogenesis is not well understood. The condition is thought to develop as a result of <em>Candida</em> spp invasion from the gastrointestinal tract into the bloodstream, in the context of prolonged neutropenia. It may represent a form of immune reconstitution syndrome, given development of symptoms and radiographic findings following neutrophil recovery. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> − Chronic disseminated candidiasis should be suspected in patients who present with fever unresponsive to broad-spectrum antibiotic therapy, usually within two weeks of neutrophil recovery. Additional signs and symptoms may include right upper quadrant tenderness, hepatomegaly, splenomegaly, nausea, vomiting, and/or anorexia. (See <a class="local">'Signs and symptoms'</a> above and <a class="local">'Clinical approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnostic evaluation should include laboratory testing (complete blood count, liver function tests, beta-D-glucan, blood cultures) and radiographic imaging (beginning with computed tomography). </p><p></p><p class="bulletIndent1">In most patients, a presumptive diagnosis of chronic disseminated candidiasis may be made based on clinical history, elevated liver function tests (particularly alkaline phosphatase concentration), and radiographic imaging demonstrating hypodense nodular lesions in the liver and/or spleen. A definitive diagnosis may be established by liver nodule biopsy in some cases; however, in practice, biopsy is done infrequently because the clinical picture and radiographic findings are generally are adequate to make a diagnosis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong>  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antifungal regimen</strong> − Management of chronic disseminated candidiasis consists of antifungal therapy. We suggest initial treatment with either a lipid formulation of amphotericin B or an echinocandin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Both of these agents have more robust evidence of efficacy (while still limited) than is available for azoles.</p><p></p><p class="bulletIndent2">Once the patient has demonstrated clinical improvement, we transition to step-down therapy with oral <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>. (See <a class="local">'Antifungal therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of persistent fever</strong> − For patients with persistent fevers despite appropriate antifungal therapy, we suggest administration of adjuvant glucocorticoids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Follow-up management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration</strong> − Antifungal therapy should be continued until there is resolution or calcification of the lesions on radiographic imaging, which usually takes approximately six months. (See <a class="local">'Follow-up management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent immunosuppression</strong> − Management of chronic disseminated candidiasis should not delay treatment of underlying malignancy. </p><p></p><p class="bulletIndent1">Following completion of treatment for chronic disseminated candidiasis, we suggest continuing <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (or restarting if previously stopped) during subsequent periods of immunosuppression (such as chemotherapy or hematopoietic stem cell transplantation) to prevent relapse (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Subsequent immunosuppression'</a> above.)</p><p></p><p class="headingAnchor" id="H1043949789"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Kieren Marr, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Rammaert B, Desjardins A, Lortholary O. New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis. Mycoses 2012; 55:e74.</a></li><li><a class="nounderline abstract_t">Masood A, Sallah S. Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment. Leuk Res 2005; 29:493.</a></li><li><a class="nounderline abstract_t">Thaler M, Pastakia B, Shawker TH, et al. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108:88.</a></li><li><a class="nounderline abstract_t">Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am 2000; 14:721.</a></li><li><a class="nounderline abstract_t">Boussen I, Lisan Q, Raffoux E, et al. Hepatosplenic Candidiasis in Patients With Hematological Malignancies: A 13-Year Retrospective Cohort Study. Open Forum Infect Dis 2022; 9:ofac088.</a></li><li><a class="nounderline abstract_t">Spindel SJ, Darouiche RO, Saeed ZA. Hepatosplenic candidiasis in non-neutropenic patients: a case report and literature survey. Int J Antimicrob Agents 1996; 7:149.</a></li><li><a class="nounderline abstract_t">van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 1998; 77:246.</a></li><li><a class="nounderline abstract_t">Cole GT, Lynn KT, Seshan KR. Evaluation of a murine model of hepatic candidiasis. J Clin Microbiol 1990; 28:1828.</a></li><li><a class="nounderline abstract_t">Pestalozzi BC, Krestin GP, Schanz U, et al. Hepatic lesions of chronic disseminated candidiasis may become invisible during neutropenia. Blood 1997; 90:3858.</a></li><li><a class="nounderline abstract_t">Anttila VJ, Elonen E, Nordling S, et al. Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clin Infect Dis 1997; 24:375.</a></li><li><a class="nounderline abstract_t">Anaissie E, Bodey GP, Kantarjian H, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991; 91:142.</a></li><li><a class="nounderline abstract_t">Ratip S, Odabaşi Z, Karti S, et al. Clinical microbiological case: chronic disseminated candidiasis unresponsive to treatment. Clin Microbiol Infect 2002; 8:435.</a></li><li><a class="nounderline abstract_t">Sallah S, Semelka RC, Wehbie R, et al. Hepatosplenic candidiasis in patients with acute leukaemia. Br J Haematol 1999; 106:697.</a></li><li><a class="nounderline abstract_t">Pagano L, Mele L, Fianchi L, et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica 2002; 87:535.</a></li><li><a class="nounderline abstract_t">Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991; 91:137.</a></li><li><a class="nounderline abstract_t">Senn L, Robinson JO, Schmidt S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46:878.</a></li><li><a class="nounderline abstract_t">Son HJ, Sung H, Park SY, et al. Diagnostic performance of the (1-3)-β-D-glucan assay in patients with Pneumocystis jirovecii compared with those with candidiasis, aspergillosis, mucormycosis, and tuberculosis, and healthy volunteers. PLoS One 2017; 12:e0188860.</a></li><li class="breakAll">Samuels BI, Pagani JJ, Libshitz HI. Radiologic features of Candida infections. In: Candidiasis: Pathogenesis, Diagnosis and Treatment, Bodey GP (Ed), Raven Press, New York 1993. p.137.</li><li><a class="nounderline abstract_t">Anttila VJ, Lamminen AE, Bondestam S, et al. Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia. Eur J Haematol 1996; 56:82.</a></li><li><a class="nounderline abstract_t">De Castro N, Mazoyer E, Porcher R, et al. Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000-2007. Clin Microbiol Infect 2012; 18:E185.</a></li><li><a class="nounderline abstract_t">Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995; 76:2357.</a></li><li><a class="nounderline abstract_t">Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997; 41:1944.</a></li><li><a class="nounderline abstract_t">Gokhale PC, Barapatre RJ, Advani SH, et al. Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report. J Cancer Res Clin Oncol 1993; 119:569.</a></li><li><a class="nounderline abstract_t">Sorà F, Chiusolo P, Piccirillo N, et al. Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B. Clin Infect Dis 2002; 35:1135.</a></li><li><a class="nounderline abstract_t">Kontny U, Walsh TJ, Rossler J, et al. Successful treatment of refractory chronic disseminated candidiasis after prolonged administration of caspofungin in a child with acute myeloid leukemia. Pediatr Blood Cancer 2007; 49:360.</a></li><li><a class="nounderline abstract_t">Hübel K, Chemnitz J, Brochhagen HG, Cornely OA. Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia. Int J Hematol 2004; 79:289.</a></li><li><a class="nounderline abstract_t">Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60:363.</a></li><li><a class="nounderline abstract_t">Poon LM, Chia HY, Tan LK, et al. Successful intensive chemotherapy followed by autologous hematopoietic cell transplantation in a patient with acute myeloid leukemia and hepatosplenic candidiasis: case report and review of literature. Transpl Infect Dis 2009; 11:160.</a></li><li><a class="nounderline abstract_t">Vehreschild JJ, Krüger K, Kurzai O, et al. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation. Mycoses 2006; 49 Suppl 1:42.</a></li><li><a class="nounderline abstract_t">Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22:651.</a></li><li><a class="nounderline abstract_t">Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 2010; 29:1043.</a></li><li><a class="nounderline abstract_t">Legrand F, Lecuit M, Dupont B, et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis 2008; 46:696.</a></li><li><a class="nounderline abstract_t">Chaussade H, Bastides F, Lissandre S, et al. Usefulness of corticosteroid therapy during chronic disseminated candidiasis: case reports and literature review. J Antimicrob Chemother 2012; 67:1493.</a></li><li><a class="nounderline abstract_t">Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis--a contraindication to marrow transplantation? Blood 1994; 84:2811.</a></li></ol></div><div id="topicVersionRevision">Topic 2425 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22360318" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755501" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3276268" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hepatic candidiasis in cancer patients: the evolving picture of the syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10987117" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35355897" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hepatosplenic Candidiasis in Patients With Hematological Malignancies: A 13-Year Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18611749" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hepatosplenic candidiasis in non-neutropenic patients: a case report and literature survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9715729" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2394804" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evaluation of a murine model of hepatic candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9354652" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hepatic lesions of chronic disseminated candidiasis may become invisible during neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114188" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1867240" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12199855" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical microbiological case: chronic disseminated candidiasis unresponsive to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468858" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatosplenic candidiasis in patients with acute leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12010669" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1867239" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hepatosplenic candidiasis: successful treatment with fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18260755" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29190812" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnostic performance of the (1-3)-β-D-glucan assay in patients with Pneumocystis jirovecii compared with those with candidiasis, aspergillosis, mucormycosis, and tuberculosis, and healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29190812" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Diagnostic performance of the (1-3)-β-D-glucan assay in patients with Pneumocystis jirovecii compared with those with candidiasis, aspergillosis, mucormycosis, and tuberculosis, and healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8600000" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22458883" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8635043" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9303390" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8335676" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384850" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16444677" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Successful treatment of refractory chronic disseminated candidiasis after prolonged administration of caspofungin in a child with acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15168600" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17526917" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Caspofungin for the treatment of less common forms of invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19228346" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Successful intensive chemotherapy followed by autologous hematopoietic cell transplantation in a patient with acute myeloid leukemia and hepatosplenic candidiasis: case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16961582" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14564539" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Voriconazole salvage treatment of invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20495990" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Posaconazole salvage treatment in paediatric patients: a multicentre survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18230039" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Adjuvant corticosteroid therapy for chronic disseminated candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22374323" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Usefulness of corticosteroid therapy during chronic disseminated candidiasis: case reports and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7919390" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hepatosplenic candidiasis--a contraindication to marrow transplantation?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
